Skip to main content
Site Search
Investors Home
News Releases
Events & Presentations
Stock Information
Stock Quote
Stock Chart
Historical Stock Quote
Investment Calculator
SEC Filings
All Filings
Quarterly Results
Annual Reports & Proxies
Analyst Coverage
Resources
Investor FAQs
Information Request Form
Investor Email Alerts
Investor Contacts
RSS Feeds
News Releases
Investors Home
News Releases
Events & Presentations
Stock Information
Stock Quote
Stock Chart
Historical Stock Quote
Investment Calculator
SEC Filings
All Filings
Quarterly Results
Annual Reports & Proxies
Analyst Coverage
Resources
Investor FAQs
Information Request Form
Investor Email Alerts
Investor Contacts
RSS Feeds
Normal
Get News Alerts by RSS
(opens in new window)
Press release year list
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
2011
12/07/2022
Puma Biotechnology Presents Updated Findings from the TBCRC-022 Trial at the 2022 San Antonio Breast Cancer Symposium
12/05/2022
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
11/03/2022
Puma Biotechnology Reports Third Quarter 2022 Financial Results
11/02/2022
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
10/27/2022
Puma Biotechnology Presents Updated Findings from the Phase II SUMMIT Basket Trial of Neratinib in EGFR Exon 18-Mutant NSCLC at the 2022 EORTC/NCI/AACR Symposium
10/20/2022
Puma Biotechnology to Host Conference Call to Discuss Third Quarter Financial Results
10/04/2022
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
09/20/2022
Puma Biotechnology Announces Exclusive License Agreement with Takeda for the Development and Commercialization of Alisertib, an Investigational Aurora Kinase A Inhibitor
09/11/2022
Puma Biotechnology Presents Updated Findings from the Phase II SUMMIT Basket Trial of Neratinib for HER2-Mutant, Recurrent/Metastatic Cervical Cancer at the ESMO Congress 2022
09/06/2022
Puma Biotechnology to Present at the H.C. Wainwright 24th Annual Global Investment Conference
09/02/2022
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
08/05/2022
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
08/04/2022
Puma Biotechnology Reports Second Quarter 2022 Financial Results
07/21/2022
Puma Biotechnology to Host Conference Call to Discuss Second Quarter Financial Results
07/06/2022
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
06/07/2022
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
06/06/2022
Puma Biotechnology Presents Outcomes from the Metastatic Breast Cancer Cohort of the SUMMIT Trial at the ASCO 2022 Annual Meeting
06/04/2022
Puma Biotechnology Presents Final Results from the Biliary Tract Cohort of the Phase 2 SUMMIT ‘Basket’ Trial of Neratinib at the ASCO 2022 Annual Meeting
05/26/2022
Puma Biotechnology Announces Publication of Abstracts on Neratinib for the 2022 ASCO Annual Meeting
05/11/2022
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
05/05/2022
Puma Biotechnology Reports First Quarter 2022 Financial Results
04/27/2022
Puma Biotechnology Announces Publication of Neratinib Abstract Titles for the 2022 ASCO Annual Meeting
04/21/2022
Puma Biotechnology to Host Conference Call to Discuss First Quarter Financial Results
04/05/2022
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
03/10/2022
Puma Biotechnology Announces $10 Million Private Placement
03/07/2022
Puma Biotechnology to Participate in Breast Cancer Panel at Cowen’s Annual Health Care Conference
03/04/2022
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
03/03/2022
Puma Biotechnology Reports Fourth Quarter and Full Year Financial Results
02/16/2022
Puma Biotechnology to Host Conference Call to Discuss Fourth Quarterand Full Year 2021 Financial Results
02/03/2022
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
01/20/2022
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
01/12/2022
Puma Biotechnology’s NERLYNX® Included in Two Important NCCN Clinical Practice Guideline Updates for the Treatment of Breast Cancer
01/10/2022
Puma Biotechnology Releases Updated Corporate Presentation
01/04/2022
Puma Biotechnology to Present at the H.C. Wainwright BioConnect Conference